Koers BioNTech SE Xetra
Aandelen
US09075V1026
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 2,75 mld. 2,94 mld. | Omzet 2025 * | 2,75 mld. 2,94 mld. | Marktkapitalisatie | 20,77 mld. 22,24 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -419 mln. -449 mln. | Nettowinst (verlies) 2025 * | -548 mln. -587 mln. | EV/omzet 2024 * | 2,95 x |
Nettoliquiditeiten 2024 * | 12,67 mld. 13,57 mld. | Nettoliquiditeiten 2025 * | 12,02 mld. 12,87 mld. | EV/omzet 2025 * | 3,18 x |
K/w-verhouding 2024 * |
-47,6
x | K/w-verhouding 2025 * |
-37,7
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 86,48% |
Recentste transcriptie over BioNTech SE
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Ugur Sahin
CEO | Chief Executive Officer | 58 | 02-06-08 |
Özlem Türeci
FOU | Founder | 57 | 02-06-08 |
Jens Holstein
DFI | Director of Finance/CFO | 60 | 01-07-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Rudolf Staudigl
BRD | Director/Board Member | 70 | 01-01-22 |
Director/Board Member | 67 | 02-06-08 | |
Helmut Jeggle
CHM | Chairman | 53 | 02-06-08 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+18,15% | 124 mld. | |
+18,02% | 112 mld. | |
+5,07% | 22,94 mld. | |
-9,86% | 17,02 mld. | |
-14,97% | 16,88 mld. | |
-39,94% | 16,87 mld. | |
+2,80% | 13,63 mld. | |
+27,39% | 11,61 mld. | |
+106,26% | 10,31 mld. |